TNF production in macrophages is genetically determined and regulates inflammatory disease in rats

Journal of Immunology

Volumn 185, Issue 1, 2010, Pages 442-450

  Gillett, Alan ^a   Marta, Monica ^a   Jin, Tao ^b   Tuncel, Jonatan ^a   Leclerc, Patrick ^a   Nohra, Rita ^a   Lange, Stefan ^b   Holmdahl, Rikard ^a   Olsson, Tomas ^a   Harris, Robert A ^a   Jagodic, Maja ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PRISTANE; TUMOR NECROSIS FACTOR; AUTACOID; TERPENE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONGENIC STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE REGULATORY NETWORK; GENETIC LINKAGE; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE ACTIVATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RAT; SEPSIS; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CHROMOSOME MAP; COMPARATIVE STUDY; CROSS BREEDING; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; MACROPHAGE; MALE; METABOLISM; METHODOLOGY; NEURITIS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, CONGENIC; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; CROSSES, GENETIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; LINKAGE (GENETICS); MACROPHAGES; MALE; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PHYSICAL CHROMOSOME MAPPING; QUANTITATIVE TRAIT LOCI; RATS; SEPSIS; SIGNAL TRANSDUCTION; TERPENES; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956209039     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0904101     Document Type: Article

References (64)

1. Carswell, E. A., L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666-3670.
2. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
3. O'Shea, J. J., A. Ma, and P. Lipsky. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2: 37-45.
4. Husby, G., and R. C. Williams, Jr. 1988. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J. Autoimmun. 1: 363-371.
5. Hofman, F. M., D. R. Hinton, K. Johnson, and J. E. Merrill. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170: 607-612.
6. Tracey, K. J., B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hariri, T. J. Fahey, III, A. Zentella, J. D. Albert, et al. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474.
7. Havell, E. A. 1989. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J. Immunol. 143: 2894-2899.
8. Klareskog, L., D. van der Heijde, J. P. de Jager, A. Gough, J. Kalden, M. Malaise, E. Martín Mola, K. Pavelka, J. Sany, L. Settas, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-681.
9. Keystone, E. C., M. H. Schiff, J. M. Kremer, S. Kafka, M. Lovy, T. DeVries, and D. J. Burge. 2004. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 50: 353-363.
10. van der Pouw Kraan, T. C., C. A. Wijbrandts, L. G. van Baarsen, F. Rustenburg, J. M. Baggen, C. L. Verweij, and P. P. Tak. 2008. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann. Rheum. Dis. 67: 563-566.
11. Hochberg, M. C., M. G. Lebwohl, S. E. Plevy, K. F. Hobbs, and D. E. Yocum. 2005. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin. Arthritis Rheum. 34: 819-836.
12. van Oosten, B. W., F. Barkhof, L. Truyen, J. B. Boringa, F. W. Bertelsmann, B. M. von Blomberg, J. N. Woody, H. P. Hartung, and C. H. Polman. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534.
13. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465.
14. Louis, E., D. Franchimont, A. Piron, Y. Gevaert, N. Schaaf-Lafontaine, S. Roland, P. Mahieu, M. Malaise, D. De Groote, R. Louis, and J. Belaiche. 1998. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin. Exp. Immunol. 113: 401-406.
15. McGuire, W., A. V. Hill, C. E. Allsopp, B. M. Greenwood, and D. Kwiatkowski. 1994. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 371: 508-510.
16. Westendorp, R. G., J. A. Langermans, T. W. Huizinga, A. H. Elouali, C. L. Verweij, D. I. Boomsma, J. P. Vandenbroucke, and J. P. Vandenbrouke. 1997. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349: 170-173.
17. Fernandez-Arquero, M., R. Arroyo, A. Rubio, C. Martin, P. Vigil, L. Conejero, M. A. Figueredo, and E. G. de la Concha. 1999. Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology 53: 1361-1363. (Pubitemid 29480107)
18. Martínez, A., M. Fernández-Arquero, D. Pascual-Salcedo, L. Conejero, H. Alves, A. Balsa, and E. G. de la Concha. 2000. Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis. Arthritis Rheum. 43: 1366-1370.
19. Xu, H., E. Wallstrom, K. Becanovic, I. Dahlman, and J. C. Lorentzen. 2002. Identification of rat quantitative trait loci that regulate LPS-induced proinflammatory cytokine responses. Scand. J. Immunol. 56: 248-253.
20. Dahlman, I., J. C. Lorentzen, K. L. de Graaf, A. Stefferl, C. Linington, H. Luthman, and T. Olsson. 1998. Quantitative trait loci disposing for both experimental arthritis and encephalomyelitis in the DA rat; impact on severity of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis and antibody isotype pattern. Eur. J. Immunol. 28: 2188-2196.
21. Remmers, E. F., R. E. Longman, Y. Du, A. O'Hare, G. W. Cannon, M. M. Griffiths, and R. L. Wilder. 1996. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat. Genet. 14: 82-85.
22. Vingsbo-Lundberg, C., N. Nordquist, P. Olofsson, M. Sundvall, T. Saxne, U. Pettersson, and R. Holmdahl. 1998. Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats. Nat. Genet. 20: 401-404.
23. Huberle, A., A. D. Beyeen, J. Ockinger, M. Ayturan, M. Jagodic, K. L. de Graaf, N. Fissolo, M. Marta, P. Olofsson, M. Hultqvist, et al. 2009. Advanced intercross line mapping suggests that ncf1 (ean6) regulates severity in an animal model of guillain-barre syndrome. J. Immunol. 182: 4432-4438.
24. Marta, M., P. Stridh, K. Becanovic, A. Gillett, J. Ockinger, J. C. Lorentzen, M. Jagodic, and T. Olsson. 2010. Multiple loci comprising immune-related genes regulate experimental neuroinflammation. Genes Immun 11: 21-36.
25. Jacob, H. J., K. Lindpaintner, S. E. Lincoln, K. Kusumi, R. K. Bunker, Y. P. Mao, D. Ganten, V. J. Dzau, and E. S. Lander. 1991. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 67: 213-224.
26. Wenz, H., J. M. Robertson, S. Menchen, F. Oaks, D. M. Demorest, D. Scheibler, B. B. Rosenblum, C. Wike, D. A. Gilbert, and J. W. Efcavitch. 1998. High-precision genotyping by denaturing capillary electrophoresis. Genome Res. 8: 69-80.
27. Schmittgen, T. D., and K. J. Livak. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3: 1101-1108.
28. Edwards, J. C., A. D. Sedgwick, and D. A. Willoughby. 1981. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J. Pathol. 134: 147-156.
29. Amor, S., N. Groome, C. Linington, M. M. Morris, K. Dornmair, M. V. Gardinier, J. M. Matthieu, and D. Baker. 1994. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J. Immunol. 153: 4349-4356.
30. Bremell, T., S. Lange, L. Svensson, E. Jennische, K. Gröndahl, H. Carlsten, and A. Tarkowski. 1990. Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum. 33: 1739-1744.
31. Bremell, T., S. Lange, R. Holmdahl, C. Rydén, G. K. Hansson, and A. Tarkowski. 1994. Immunopathological features of rat Staphylococcus aureus arthritis. Infect. Immun. 62: 2334-2344.
32. Helle, M., L. Boeije, and L. A. Aarden. 1988. Functional discrimination between interleukin 6 and interleukin 1. Eur. J. Immunol. 18: 1535-1540.
33. Broman, K. W., H. Wu, S. Sen, and G. A. Churchill. 2003. R/qtl: QTL mapping in experimental crosses. Bioinformatics 19: 889-890.
34. Dupuis, J., and D. Siegmund. 1999. Statistical methods for mapping quantitative trait loci from a dense set of markers. Genetics 151: 373-386. (Pubitemid 29031902)
35. Butler, G. S., S. S. Apte, F. Willenbrock, and G. Murphy. 1999. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J. Biol. Chem. 274: 10846-10851.
36. Miller, A. J., G. N. Luheshi, N. J. Rothwell, and S. J. Hopkins. 1997. Local cytokine induction by LPS in the rat air pouch and its relationship to the febrile response. Am. J. Physiol. 272: R857-R861.
37. Kollias, G., E. Douni, G. Kassiotis, and D. Kontoyiannis. 1999. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann. Rheum. Dis. 58(Suppl 1): I32-I39.
38. Cerami, A., Y. Ikeda, N. Le Trang, P. J. Hotez, and B. Beutler. 1985. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol. Lett. 11: 173-177.
39. Dendrou, C. A., V. Plagnol, E. Fung, J. H. Yang, K. Downes, J. D. Cooper, S. Nutland, G. Coleman, M. Himsworth, M. Hardy, et al. 2009. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 41: 1011-1015.
40. Lowe, C. E., J. D. Cooper, T. Brusko, N. M. Walker, D. J. Smyth, R. Bailey, K. Bourget, V. Plagnol, S. Field, M. Atkinson, et al. 2007. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39: 1074-1082.
41. Ridker, P. M., E. Danielson, F. A. Fonseca, J. Genest, A. M. Gotto, Jr., J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. Macfadyen, et al; JUPITER Trial Study Group. 2009. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175-1182.
42. Klareskog, L., A. I. Catrina, and S. Paget. 2009. Rheumatoid arthritis. Lancet 373: 659-672.
43. Pandey, S., and D. K. Agrawal. 2006. Immunobiology of Toll-like receptors: emerging trends. Immunol. Cell Biol. 84: 333-341.
44. Doyle, S., S. Vaidya, R. O'Connell, H. Dadgostar, P. Dempsey, T. Wu, G. Rao, R. Sun, M. Haberland, R. Modlin, and G. Cheng. 2002. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 17: 251-263.
45. Jones, B. W., T. K. Means, K. A. Heldwein, M. A. Keen, P. J. Hill, J. T. Belisle, and M. J. Fenton. 2001. Different Toll-like receptor agonists induce distinct macrophage responses. J. Leukoc. Biol. 69: 1036-1044.
46. Sariban, E., K. Imamura, R. Luebbers, and D. Kufe. 1988. Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J. Clin. Invest. 81: 1506-1510.
47. Ortiz-Ortiz, L., R. M. Nakamura, and W. O. Weigle. 1976. T cell requirement for experimental allergic encephalomyelitis induction in the rat. J. Immunol. 117: 576-579.
48. Vingsbo, C., P. Sahlstrand, J. G. Brun, R. Jonsson, T. Saxne, and R. Holmdahl. 1996. Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am. J. Pathol. 149: 1675-1683.
49. Stuart, J. M., M. A. Cremer, A. S. Townes, and A. H. Kang. 1982. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J. Exp. Med. 155: 1-16.
50. Hauser, S. L., A. K. Bhan, F. Gilles, M. Kemp, C. Kerr, and H. L. Weiner. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 19: 578-587.
51. Lampert, P., and S. Carpenter. 1965. Electron Microscopic Studies on the Vascular Permeability and the Mechanism of Demyelination in Experimental Allergic Encephalomyelitis. J. Neuropathol. Exp. Neurol. 24: 11-24.
52. Yanni, G., A. Whelan, C. Feighery, and B. Bresnihan. 1994. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann. Rheum. Dis. 53: 39-44.
53. Sohn, H., K. W. Kim, H. B. Kang, C. J. Won, W. S. Kim, B. Lee, O. J. Kwon, W. J. Koh, S. J. Shin, and H. J. Kim. 2010. Induction of macrophage death by clinical strains of Mycobacterium kansasii. Microb. Pathog. 48: 160-167.
54. Green, E. A., E. E. Eynon, and R. A. Flavell. 1998. Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 9: 733-743.
55. Campbell, I. K., K. O'Donnell, K. E. Lawlor, and I. P. Wicks. 2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J. Clin. Invest. 107: 1519-1527.
56. Körner, H., D. S. Riminton, D. H. Strickland, F. A. Lemckert, J. D. Pollard, and J. D. Sedgwick. 1997. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J. Exp. Med. 186: 1585-1590.
57. Eugster, H. P., K. Frei, R. Bachmann, H. Bluethmann, H. Lassmann, and A. Fontana. 1999. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur. J. Immunol. 29: 626-632.
58. Pfeffer, K., T. Matsuyama, T. M. Kündig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Krönke, and T. W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457-467.
59. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664.
60. Grivennikov, S. I., A. V. Tumanov, D. J. Liepinsh, A. A. Kruglov, B. I. Marakusha, A. N. Shakhov, T. Murakami, L. N. Drutskaya, I. Förster, B. E. Clausen, et al. 2005. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity 22: 93-104.
61. Christen, U., T. Wolfe, U. Möhrle, A. C. Hughes, E. Rodrigo, E. A. Green, R. A. Flavell, and M. G. von Herrath. 2001. A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J. Immunol. 166: 7023-7032. (Pubitemid 32525571)
62. Kassiotis, G., and G. Kollias. 2001. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 193: 427-434.
63. Mohan, N., E. T. Edwards, T. R. Cupps, P. J. Oliverio, G. Sandberg, H. Crayton, J. R. Richert, and J. N. Siegel. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44: 2862-2869.
64. Plenge, R. M., and L. A. Criswell. 2008. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr. Opin. Rheumatol. 20: 145-152.